Abstract
Ublituximab (BRIUMVITM), an anti-CD20 immunoglobulin G1 monoclonal antibody, is a promising new treatment option for patients with relapsing forms of ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
